Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran

Annals of Oncology

Volumn 17, Issue 7, 2006, Pages 1166-1171

  Safarinejad, M R ^a,b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE   (Iran)

Author keywords

Epidemiology; Prostate cancer; Prostatic specific antigen; Screening

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; ETHNOLOGY; GLEASON SCORE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; TRANSRECTAL ULTRASONOGRAPHY; VOLUNTEER;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; FALSE POSITIVE REACTIONS; HUMANS; IRAN; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33745634639     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl087     Document Type: Article

References (47)

1. MacMahon B, Pugh TF. Epidemiology; Principles and Methods. Boston: Little Brown, 1970.
2. Gronberg H. Prostate cancer epidemiology. Lancet 2003 8; 361(9360): 859-64.
3. Parkin DM, Pisani P, Ferlay J. Estimates of the world-wide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 827-41.
4. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: The global picture. Eur J Cancer 2001; 37 (Suppl. 8): 4-66.
5. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in Five Continents, Vol. VIII. Lyon, IARC Scientific Publications no. 155, 2002.
6. Gohji K, Nomi M, Egawa S et al. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. Cancer 1997; 79(10): 1969-76.
7. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, version 1.0. IARC CancerBase no. 5. Lyon, IARC Press, 2001.
8. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995; 55: 1937-1940.
9. Rooney C, Devis T. Mortality trends by cause of death in England and Wales 1980-94: The impact of introducing automated cause coding and related changes in 1993. Population Trends 1996; 86: 29-35.
10. Hakama M, Stenman UH, Aromaa A et al. Validity of the prostate specific antigen test for prostate cancer screening: Followup study with a bank of 21,000 sera in Finland. J Urol 2001; 166(6): 2189-91.
11. Brawer MK, Chetner MP, Beatie J et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841-845.
12. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61.
13. Labrie F, Dupont A, Suburu R et al. Serum prostate specific antigen as prescreening test for prostate cancer. J Urol 1992; 147: 846-852.
14. Auvinen A, Maattanen L, Finne P et al. Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial. Int J Cancer. 2004; 111(6): 940-3.
15. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548-52.
16. Stephenson RA, Smart CR, Mineau GP et al. The fall in incidence of prostatic carcinoma. On the down side of a Prostate Specific Antigen induced peak in incidence-data from Utah Cancer Registry. Cancer 1996; 77: 1342-8.
17. Legler JM, Feuer EJ, Potosky AL et al. The role of prostate specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control 1998; 9: 519-27.
18. Stenman UH, Leinonen J, Alfthan H et al. A complex between prostate-specific antigen and a1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6.
19. Christensson A, Bjork T, Nilsson O et al. Serum-prostate specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-5.
20. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate specific antigen-based screening. JAMA 1993; 270: 948-54.
21. Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage of localised prostate cancer. J Urol 1993; 150: 110-4.
22. Myrtle JF, Klimley PG, Ivor LP, Bruni JF. Clinical utility of prostate specific antigen (PSA) in the management of prostatic cancer. Advances in cancer diagnosis. San Diego: Hybriditech Inc. 1986: 2-3.
23. Kupelian P, Katcher J, Levin H, Zippe C, Klein E. Correlation of clinical and pathologic factors with rising prostate specific antigen profiles after radical prostatectomy alone for clinically localised prostate cancer. Urology 1996; 48: 249-54.
24. Mitrunen K, Pettersson K, Piironen T et al. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995; 4: 1115-20.
25. Pettersson K, Piironen T, Seppala M et al. Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSAalpha-1-antichymotrypsin complex. Clin Chem 1995; 41: 1480-8.
26. Schröder FH, Hermanek P, Denis L et al. The TNM classification of prostate cancer. Prostate 1992; 4 (suppl.): 129-38.
27. Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of prostate tumors. In: Mostofi FK. International Histological Classification of Tumors No. 22. Geneva: World Health Organization, 1980: 1-26.
28. Union Internationale Contre le Cancer. TNM classification of malignant tumours, 4th edn. Berlin: Union Internationale Contre le Cancer, 1992.
29. Gleason DF. Veterans Administration Cooperative Urological Research Group. Histologic grading and staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: The prostate. Philadelphia: Lea & Febiger, 1977: 171-198.
30. Reissigl A, Pointner J, Horninger W et al. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: Results of a large screening study. Urology 1995; 46: 662-5.
31. Andriole GL, Catalona WJ. Using PSA to screen for prostate cancer. The Washington University experience. Urol Clin North Am 1993; 20: 647-51.
32. Labrie F, Candas B, Cusan L et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996; 47: 212-7.
33. Hugosson J, Aus G, Bergdahl S et al. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int 2003; 92 Suppl 2: 39-43.
34. Gustafsson O, Mansour E, Norming U et al. Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer - a study of a randomly selected population of 2,400 men. Scand J Urol Nephrol. 1998; 32(6): 373-7.
35. Horninger W, Reissigl A, Rogatsch H et al. Prostate cancer screening in the Tyrol, Austria: Experience and results. Eur J Cancer. 2000; 36(10): 1322-35.
36. Uchida K, Takeshima H, Akaza H, Ono Y. Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: results of the health checkup system. Jpn J Clin Oncol 2000; 30(2): 95-100.
37. Egawa S, Suyama K, Ohori M et al. Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan. Cancer. 1995; 76(3): 463-72.
38. Brawer MK, Beatie J, Wener MH et al. Screening for prostatic carcinoma with prostate specific antigen: Results of the second year. J Urol 1993; 150: 106-109.
39. Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer I. Results of a retrospective evaluation of 1726 men. Urology 1995; 46: 773-8.
40. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452-5.
41. Tanguay S, Begin LR, Elhilali MM et al. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002; 59: 261-5.
42. Fowler JE Jr, Sanders J, Bigler SA et al. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5-9.9 ng/ml. J Urol 2000; 163: 1467-70.
43. Stormont TJ, Farrow GM, Myers RP et al. Clinical stage B0 or T1c prostate cancer: Nonpalpable disease identified by an elevated serum prostate specific antigen concentration. Urology 1993; 41: 3-8.
44. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374.
45. Smith DS, Catalona WJ. The nature of prostate cancer detected through PSA based screening. J Urol 1994; 152: 1732-1736.
46. Crawford ED, De Antoni EP. PSA as a screening test for prostate cancer. Urol Clin North Am 1993; 20: 637-46.
47. Sakr WA, Haas GP, Cassin BF et al. The frequency of carcinomas and intraepithelial neoplasia of the prostate in young male patients. J Urol 1995; 150: 379-385.